May 3, 2018 / 12:48 PM / 22 days ago

BRIEF-Aequus Receives Positive FDA Regulatory Guidance For Anti-Nausea Patch

May 3 (Reuters) - Aequus Pharmaceuticals Inc:

* AEQUUS RECEIVES POSITIVE FDA REGULATORY GUIDANCE FOR ANTI-NAUSEA PATCH

* AEQUUS PHARMACEUTICALS INC - FDA HAS CONFIRMED THAT AN ABBREVIATED 505(B)(2) REGULATORY PATHWAY WOULD BE APPROPRIATE FOR SUBMISSION OF AQS1303

* AEQUUS PHARMACEUTICALS - FDA INDICATED BIOEQUIVALENCE STUDY TO BRIDGE ORAL DICLEGIS(®) SAFETY AND EFFICACY DATA WITH AQS1303 IS LIKELY ACCEPTABLE

* AEQUUS PHARMACEUTICALS INC - FDA HAS AGREED WITH AEQUUS’ PROPOSED CLINICAL PLAN FOR AQS1303

* AEQUUS PHARMACEUTICALS-RECEIVED POSITIVE FEEDBACK FROM U.S. FDA ON ITS PRE-IND SUBMISSION FOR CO’S LONG-ACTING ANTI-NAUSEA TRANSDERMAL PATCH, AQS1303 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below